KIORA PHARMACEUTICALS INC (KPRX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.38

From 52W high−16.78%

Volume3537.00

Market cap$10.53M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$2.38

From 52W high

−16.78%

Volume

3537.00

Market cap

$10.53M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

P/E (TTM)

—

RSI (14)

33.1

MomentumView details →

1D Return

−0.83%

YTD Return

+20.56%

SummaryUpdated Jun 1, 2026

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is a clinical-stage specialty pharmaceutical company founded in 1998 and headquartered in Salt Lake City, Utah. Originally incorporated as Eyegate Pharmaceuticals, the company rebranded to Kiora Pharmaceuticals in November 2021. The company went public in February 2015 and focuses exclusively on developing innovative therapies for ophthalmic diseases. As a clinical-stage biotechnology firm, Kiora currently generates minimal revenue while investing heavily in research and development of three primary drug candidates targeting various eye conditions.

Ask drillr about KIORA PHARMACEUTICALS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−65.18%

ROA (TTM)

−46.21%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+23.66%

FCF YoY

−10.05%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

—

EBITDA YoY

−29.78%

MomentumView details →

1D Return

−0.83%

YTD Return

+20.56%

1Y Return

−6.86%

RSI (14)

33.1

vs 50D SMA

−7.99%

vs 200D SMA

−1.53%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

8.97x

Quick Ratio

8.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

27.66%

Beats (12Q)

8/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

2.14%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−10.99M

Op. CF (TTM)

−8.51M

Next earningsNov 6, 2026 →

Latest newsMore news →

Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 1, 2026.41d ago

Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation an exclusive, sublicensable license to develop, manufacture, and commercialize its KIO-301 product for ophthalmology indications in South Korea, in exchange for a $1.0 million upfront fee, milestone payments, and double-digit royalties.62d ago

Similar companies

Adial Pharmaceuticals, Inc.ADIL Pluri Inc.PLUR Intensity Therapeutics, Inc.INTS IN8bio, Inc.INAB Cellectar Biosciences, Inc.CLRB Lisata Therapeutics, Inc.LSTA Find similar companies →

Latest newsMore news →

Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 1, 2026.41d ago Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation an exclusive, sublicensable license to develop, manufacture, and commercialize its KIO-301 product for ophthalmology indications in South Korea, in exchange for a $1.0 million upfront fee, milestone payments, and double-digit royalties.62d ago